Patents by Inventor Tho V. Thieu

Tho V. Thieu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
    Patent number: 11919881
    Abstract: The present invention provides imidazole substituted pyridine N-oxide derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: March 5, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Guozhang Xu, Tho V. Thieu, Zhijie Liu, Micheal D. Gaul
  • Pyridine N-oxide derivatives useful as factor XIa inhibitors
    Patent number: 11814364
    Abstract: The present invention is directed to pyridine N-oxide derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: November 14, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Guozhang Xu, Boying Guo, Zhijie Liu, Jing Zhang, Micheal D. Gaul, Eugene B. Grant, Mark J. Macielag, Tianbao Lu, Tho V. Thieu
  • COMPOUNDS USEFUL AS FACTOR XIA INHIBITORS
    Publication number: 20230312560
    Abstract: The present invention is directed to Factor XIa inhibitors, tautomers, stereoisomers, isotopologues, and pharmaceutically acceptable salts and solvates thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders, and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Application
    Filed: July 21, 2021
    Publication date: October 5, 2023
    Inventors: Guozhang XU, Mark J. MACIELAG, Zhijie LIU, Tho V. THIEU, Ravi NARGUND
  • 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS
    Publication number: 20230295157
    Abstract: The present invention is directed to 3-(1H-imidazol-2-yl)-2,3,8,8a-tetrahydroindolizin-5(1H)-one derivatives, stereoisomers, isotopologues, and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Application
    Filed: July 22, 2021
    Publication date: September 21, 2023
    Inventors: Guozhang XU, Micheal D. GAUL, Tho V. THIEU, Jing ZHANG, Mark WALL, Ling Hua GAO, Bin ZHU, Tianbao LU, Boying GUO, Zhijie LIU, Ravi NARGUND, Mark J. MACIELAG
  • Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors
    Publication number: 20230097157
    Abstract: The present invention is directed to bicyclic pyridinon-2-one and pyrimidin-4-one derivatives, stereoisomers, isotopologues, and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Application
    Filed: July 21, 2022
    Publication date: March 30, 2023
    Inventors: Guozhang Xu, Mark J. Macielag, Micheal D. Gaul, Tho V. Thieu, Zhijie Liu
  • PYRIDINE N-OXIDE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS
    Publication number: 20230091768
    Abstract: The present invention is directed to pyridine N-oxide derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Application
    Filed: March 17, 2022
    Publication date: March 23, 2023
    Inventors: Guozhang Xu, Boying Guo, Zhijie Liu, Jing Zhang, Micheal D. Gaul, Eugene B. Grant, Mark J. Macielag, Tianbao Lu, Tho V. Thieu
  • SUBSTITUTED PYRIDINE N-OXIDE DERIVATIVES USEFUL AS A FACTOR XIA INHIBITORS
    Publication number: 20220315561
    Abstract: The present invention provides imidazole substituted pyridine N-oxide derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Application
    Filed: March 17, 2022
    Publication date: October 6, 2022
    Inventors: Guozhang Xu, Tho V. Thieu, Zhijie Liu, Micheal D. Gaul
  • Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors
    Publication number: 20120165519
    Abstract: The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: March 6, 2012
    Publication date: June 28, 2012
    Applicant: Cephalon, Inc.
    Inventors: Gulzar Ahmed, Henry Joseph Breslin, Jason Burke, Matthew A. Curry, James L. Diebold, Bruce Dorsey, Benjamin J. Dugan, Daming Feng, Diane E. Gingrich, Tao Guo, Keith S. Learn, Joseph G. Lisko, Rong-qiang Liu, Eugen Mesaros, Karen Milkiewicz, Gregory R. Ott, Jay P. Theroff, Tho V. Thieu, Rabindranath Tripathy, Theodore L. Underiner, Gregory J. Wells, Craig A. Zificsak
  • Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
    Patent number: 8148391
    Abstract: The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: October 23, 2007
    Date of Patent: April 3, 2012
    Assignee: Cephalon, Inc.
    Inventors: Gulzar Ahmed, Henry Joseph Breslin, Jason Burke, Matthew A. Curry, James L. Diebold, Bruce Dorsey, Benjamin J. Dugan, Daming Feng, Diane E. Gingrich, Tao Guo, Keith S. Learn, Joseph G. Lisko, Rong-Qiang Liu, Eugen Florin Mesaros, Karen Milkiewicz, Gregory R. Ott, Jay P. Theroff, Tho V. Thieu, Rabindranath Tripathy, Theodore L. Underiner, Gregory J. Wells, Craig A. Zificsak
  • FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS
    Publication number: 20090221555
    Abstract: The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: October 23, 2007
    Publication date: September 3, 2009
    Applicants: Cephalon, Inc., Pharmacopeia Drug Discovery, Inc.
    Inventors: Gulzar Ahmed, Adolph Bohnstedt, Henry Joseph Breslin, Jason Burke, Matthew A. Curry, James L. Diebold, Bruce Dorsey, Benjamin J. Dugan, Daming Feng, Diane E. Gingrich, Tao Guo, Koc-Kan Ho, Keith S. Learn, Joseph G. Lisko, Rong-qiang Liu, Eugen Mesaros, Karen Milkiewicz, Gregory R. Ott, Jonathan Parrish, Jay P. Theroff, Tho V. Thieu, Rabindranath Tripathy, Theodore L. Underiner, Jason C. Wagner, Linda Weinberg, Gregory J. Wells, Ming You, Craig A. Zificsak
  • Factor Xa compounds
    Patent number: 7446210
    Abstract: The present invention is directed to novel compounds of Formula I: and forms and pharmaceutical compositions thereof, and the use thereof as inhibitors of Factor Xa.
    Type: Grant
    Filed: October 24, 2005
    Date of Patent: November 4, 2008
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Tianbao Lu, Tho V. Thieu, Yu-Kai Lee, Daniel J. Parks, Thomas P. Markotan, Wenxi Pan, Karen L. Milkiewicz, Mark R. Player